Boyapati A, et al. High Baseline Serum IL-6 Identifies a Subgroup of Rheumatoid Arthritis Patients with Rapid Joint Damage and Clinical Progression and Predicts Increased Sarilumab Treatment Response. ACR 2018, abstract L08.
MUC5B-promotervariant rs35705950 risicofactor voor RA-geassocieerde ILD
feb 2019 | ILD, Pneumonie, RA